Gilead Sciences Announces Fourth Quarter and Full Year 2012 Financial Results
On 4 February 2013, Gilead announced details of its antiviral product sales which increased 17 percent to $2.17 billion for the fourth quarter of 2012, up from $1.86 billion for the fourth quarter of 2011.
This reflects sales growth of 20 percent in the U.S. and 9 percent in Europe.
For 2012, antiviral product sales increased 15 percent to $8.14 billion from $7.05 billion in 2011, reflecting sales growth of 21 percent in the U.S. and 6 percent in Europe.
Source: Gilead press release. Gilead Sciences announces fourth quarter and full year 2012 financial results. (4 February 2013).
Links to other websites are current at date of posting but not maintained.
This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)